Quantcast
Last updated on April 18, 2014 at 15:29 EDT

Latest Sunitinib Stories

2008-08-08 09:00:28

The UK's cost-effectiveness watchdog NICE has delivered another blow to the developers of targeted cancer therapies by recommending against the use of four new kidney cancer drugs in the UK. This recommendation suggests that NICE is likely to look unfavorably on a number of other targeted therapies in development, severely limiting future growth of the targeted cancer therapies market in the UK. In its preliminary guidance report on a number of new targeted cancer therapies, the UK's...

2008-08-08 00:00:39

Britain's National Health Service said it rejected four new drugs designed to treat advanced kidney cancer because the cost is too high. The National Institute for Health and Clinical Excellence said the drugs -- Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus) -- are too expensive and the money can be better put to other use, the Times of London said Thursday. The newspaper said cancer organizations are outraged by the decision. Advocates for the...

2008-08-08 00:00:11

By Ian Johnston CAMPAIGNERS EXPRESSED outrage yesterday at a decision to deny four drug treatments to NHS patients with advanced kidney cancer. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus). This leaves patients with only one treatment option - interferon. Professor John Wagstaff, from the South Wales Cancer Institute, said there was "no...

2008-08-08 00:00:11

By JEREMY LAURANCE The big question Why are we asking this now? CANCER CHARITIES, kidney specialists and campaigners were outraged yesterday when the National Institute for Clinical Excellence (Nice), announced that it had rejected four new drugs for advanced kidney cancer as too expensive for the NHS. In draft guidance, the medicines watchdog said that the drugs can extend life by five to six months on average but they cost too much. The money would do more good if it were spent...

2008-08-07 18:00:00

By JANE KIRBY PATIENTS with advanced kidney cancer will be denied four treatments on the NHS under new guidelines published yesterday. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus). Primary care trusts in Merseyside and Cheshire had already agreed to start offering Sutent on the NHS, as reported by the Daily Post in December last year....

2008-08-07 18:00:00

By Greg Tindle A WELSH cancer expert has described as "an outrage" plans to deny patients with advanced kidney cancer four types of drug treatment on the NHS. Under new guidelines the National Institute for Health and Clinical Excellence (Nice) - the Government's medicines watchdog - has turned down the use of the drugs saying they are not cost effective. Charities have expressed concern at the decision, saying it has left patients only one treatment option - interferon - to which...

2008-08-07 18:00:23

By Emma Brady Midland cancer experts have hit out at a decision to deny kidney cancer patients four drugs under new NHS guidelines issued yesterday. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus) which cost between pounds 20,000 and pounds 35,000 per patient per year. This leaves just one cancer drug, interferon, to which many patients...

2008-08-07 18:00:00

By HELEN RAE PATIENTS with advanced kidney cancer will be denied four life- extending treatments on the NHS because they are not cost effective. The National Institute for Health and Clinical Excellence (Nice) yesterday issued draft guidance rejecting the drugs Sutent (Sunitinib), Avastin, Nexavar and Torisel. Charities expressed outrage at the decision, saying it left patients only one treatment option - Interferon - to which many do not respond. Cancer sufferer Ken Potts, 55, of...

2008-08-07 12:00:18

PATIENTS with advanced kidney cancer will be denied four treatments on the NHS under new guidelines published today. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus). Charities expressed outrage at the decision, saying it left patients only one treatment option - interferon - to which many do not respond. Professor John Wagstaff, from the...

2008-08-07 12:00:18

By JANE KIRBY Broadcaster James Whale accused a health watchdog today of being "barbaric" in denying kidney cancer patients access to four drugs. The star, who was diagnosed with the disease in 2000 and set up a charity to raise awareness, said the National Institute for Health and Clinical Excellence (Nice) was a "very badly named organisation". He slammed Nice's decision - which is subject to appeal - to deny patients access to Sutent (sunitinib), Avastin (bevacizumab), Nexavar...